live oral poliovirus type 1, 2 and 3
Trade name: Trivalent oral polio vaccine - Sabin
Vaccineapproved
Approved
Jun 25, 1963
Clinical trial activity
32 trials · 39 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
17
Phase 3
12
Phase 4
12
Earliest trial started Mar 1, 2005 (NCT00263666)
Timeline
Indications
Approved for
Studied for
- Child · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Healthy Volunteers · Phase 4
- Malaria · Phase 3
- Malaria Vaccines · Phase 3
- Measles · Phase 4
- Morbidity · Phase 4
- Mortality · Phase 4
- Poliomyelitis · Phase 4
- Poliovirus Vaccine, Oral · Phase 4
- Rotavirus Infections · Phase 2
- Streptococcal Infections · Phase 3
- Tuberculosis · Phase 2
- Vaccination · Phase 4
- Vaccines · Phase 4
Mechanism of action
- PoliovirusImmunity, active
Poliovirus immunity, active
Approval history
- approvedJun 25, 1963
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- live attenuated poliomyelitis vaccine
- live oral poliovirus type 1, 2 and 3
- oral polio vaccine (opv) (also called trivalent oral polio vaccine or sabin vaccine)
- polio sabin
- sabin ipv
- sabin-ipv
- trivalent opv
- trivalent oral polio vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06266754 | Phase 4 | Jan 29, 2024 | Bandim Health Project, Radboud University |
| NCT05850364 | Phase 3 | May 22, 2023 | International Center for Diarrheal Disease Research, Sinovac Biotech Co., Ltd |
| NCT04529538 | Phase 1 | Jan 31, 2021 | Bill and Melinda Gates Foundation, Centers for Disease Control and Prevention (CDC), Dartmouth University, PATH, The EMMES Corporation, University of North Carolina at Chapel Hill, University of Vermont, Viroclinics Biosciences B.V. |
| NCT04054882 | Phase 4 | Aug 31, 2019 | Beijing Tiantan Bio Co., Ltd, Chengdu Institute of Biological Products Co.,Ltd., China National Biotec Group Co., Ltd, Government of China, Peking University |
| NCT04053010 | Phase 4 | Aug 10, 2019 | Beijing Tiantan Bio Co., Ltd, China National Biotec Group Co., Ltd, Government of China, Wuhan Institute of Biological Products Co., Ltd |
| NCT03581734 | Phase 3 | Jul 1, 2018 | Centers for Disease Control and Prevention (CDC), International Center for Diarrheal Disease Research, Stanford University |
| NCT03597919 | Phase 4 | May 28, 2018 | Centers for Disease Control and Prevention, China, Government of China, World Health Organization |
| NCT03546634 | Phase 4 | May 28, 2018 | Centers for Disease Control and Prevention, China, Government of China |
| NCT03092791 | Phase 1/Phase 2 (Phase 2) | Jun 7, 2017 | Takeda |
| NCT03147560 | Phase 4 | May 2, 2017 | China National Biotec Group Co., Ltd, Government of China |
| NCT03460002 | Phase 4 | Nov 30, 2016 | Bandim Health Project, Statens Serum Institut |
| NCT02582255 | Phase 4 | Nov 1, 2015 | Bill and Melinda Gates Foundation, Fidec Corporation, Vilnius University |
| NCT02521974 | Phase 4 | Oct 1, 2015 | Bill and Melinda Gates Foundation, Fidec Corporation |
| NCT02207816 | Phase 3 | Sep 18, 2014 | GlaxoSmithKline |
| NCT01870206 | Phase 3 | Jun 1, 2013 | Laboratorios de Biologicos y Reactivos de México, S.A. de C.V. |
| NCT01831050 | Phase 4 | May 1, 2013 | Bill and Melinda Gates Foundation, Centers for Disease Control and Prevention (CDC), Fidec Corporation, University of Colorado, Denver |
| NCT01813604 | Phase 3 | Nov 1, 2012 | Centers for Disease Control and Prevention (CDC), Government of Bangladesh, International Center for Diarrheal Disease Research, NanoPass Technologies Ltd |
| NCT01633216 | Phase 4 | May 1, 2012 | International Center for Diarrheal Disease Research |
| NCT01709071 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2012 | National Institute for Public Health and the Environment (RIVM), National Institute for Public Health and the Environment, RIVM, Holland, World Health Organization |
| NCT01345240 | Phase 3 | Nov 1, 2011 | GlaxoSmithKline |
Showing 20 of 32 trials
Page 1 / 2
Organizations
Research & Development (39)
39 organizations
Page 1 / 2